Contrasting Ernexa Therapeutics (ERNA) & Its Rivals

Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) is one of 843 public companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Ernexa Therapeutics to related businesses based on the strength of its risk, valuation, profitability, institutional ownership, dividends, earnings and analyst recommendations.

Profitability

This table compares Ernexa Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ernexa Therapeutics N/A -332.20% -187.38%
Ernexa Therapeutics Competitors -12,319.70% -407.93% -30.95%

Earnings & Valuation

This table compares Ernexa Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Ernexa Therapeutics $580,000.00 -$14.08 million -0.13
Ernexa Therapeutics Competitors $730.22 million $10.70 million -18.81

Ernexa Therapeutics’ rivals have higher revenue and earnings than Ernexa Therapeutics. Ernexa Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

Ernexa Therapeutics has a beta of 2.75, indicating that its share price is 175% more volatile than the S&P 500. Comparatively, Ernexa Therapeutics’ rivals have a beta of -1.88, indicating that their average share price is 288% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Ernexa Therapeutics and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ernexa Therapeutics 1 1 1 0 2.00
Ernexa Therapeutics Competitors 9916 15312 45656 1602 2.54

Ernexa Therapeutics presently has a consensus price target of $30.00, suggesting a potential upside of 1,685.71%. As a group, “Biotechnology” companies have a potential upside of 126.08%. Given Ernexa Therapeutics’ higher probable upside, equities research analysts clearly believe Ernexa Therapeutics is more favorable than its rivals.

Institutional & Insider Ownership

70.6% of Ernexa Therapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 0.5% of Ernexa Therapeutics shares are owned by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Ernexa Therapeutics rivals beat Ernexa Therapeutics on 7 of the 13 factors compared.

About Ernexa Therapeutics

(Get Free Report)

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Receive News & Ratings for Ernexa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ernexa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.